IDH1 and glioblastoma: When the patients were divided into primary and secondary GBM the most favourable group included patients with secondary GBM and IDH1/IDH2 mutations (median OS: 68.6 months) while the worst was primary GBM with no IDH1/IDH2 aberrations (median OS: 5.5 months).